Indication

Multicentric Castleman's disease

Multicentric Castleman's disease is a rare, life-threatening lymphoproliferative disorder that affects multiple lymph node stations and lymphoid tissues throughout the body. Read more about Multicentric Castleman's disease

4 drugs 4 manufacturers

Advertisement

Drugs that treat it

Common Multicentric Castleman's disease therapies.

Showing 1–4 of 4 drugs

SYLVANT (siltuximab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·MULTICENTRIC CASTLEMAN'S DISEASE
EUSA PHARMA

SYLVANT (siltuximab)

MONOCLONAL ANTIBODY, HUMAN INTERLEUKIN 6 INHIBITORS·MULTICENTRIC CASTLEMAN'S DISEASE
RECORDATI RARE
Filter & compare in the drug finder →Opens the drug finder with Multicentric Castleman's disease preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Multicentric Castleman's disease.

Multicentric Castleman's disease is a rare, life-threatening lymphoproliferative disorder that affects multiple lymph node stations and lymphoid tissues throughout the body.

It can manifest across broad adult populations as either idiopathic or associated with human herpesvirus 8 (HHV-8), the latter frequently occurring alongside human immunodeficiency virus (HIV) co-infection.

Pathophysiologically, the disease is driven by a hyperinflammatory cytokine storm—predominantly involving interleukin-6 (IL-6)—which leads to characteristic histopathological lymphadenopathy, polyclonal hypergammaglobulinemia, and profound systemic manifestations including fevers, night sweats, cytopenias, hepatosplenomegaly, and progressive multi-organ dysfunction.

Personalize your experience

Follow Multicentric Castleman's disease and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it